Terns Pharmaceuticals, Inc. (TERN)

Terns Pharmaceuticals, Inc. (Nasdaq: TERN) is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule-based product candidates to treat serious diseases, including obesity and oncology. Led by CEO Amy Burroughs, the company’s mission is to deliver best-in-class, highly differentiated oral therapies that address significant unmet medical needs. Terns envisions a future where its "Terns-601" oral GLP-1 receptor agonist disrupts the multi-billion dollar weight-loss market. As a high-growth biotech player, TERN stock is a key focus for investors seeking exposure to the next generation of oral obesity treatments and allosteric BCR-ABL inhibitors.

The business operations of Terns Pharmaceuticals in late 2025 are centered on the rapid advancement of its obesity and oncology pipelines. In December 2025, TERN stock investors focused on the pivotal Phase 2 data for "Terns-601," which aims to offer a more convenient oral alternative to injectable weight-loss drugs. The company’s core products include its oral GLP-1 agonist and "Terns-701," an allosteric BCR-ABL inhibitor for chronic myeloid leukemia. The future business strategy for TERN stock involves securing a strategic commercial partnership with a "Big Pharma" player to fund late-stage clinical trials and global commercialization. Throughout 2025, the company successfully fortified its balance sheet with a $150 million capital raise, providing a cash runway into 2027. As the obesity market shifts toward oral formulations, the specialized metabolic expertise provided by TERN stock has become a high-value asset, supporting the long-term growth case for the stock.

Terns Pharmaceuticals stock is listed on the Nasdaq Capital Market under the ticker symbol TERN. In late 2025, the TERN stock price has been highly volatile, recently trading near $12 as investors anticipate upcoming clinical catalysts. Analysts monitoring the TERN stock price highlight the massive blockbuster potential of an oral GLP-1 therapy. For those tracking the TERN stock price today, the key catalysts include Phase 3 trial design announcements and partnership discussions. As a high-conviction biotech selection, TERN stock remains a favorite for investors betting on metabolic innovation. The movement of the TERN stock price reflects the high-stakes potential of its clinical breakthroughs.